Biotechnology News

EMERYVILLE, Calif.--(BUSINESS WIRE)--Fauna Bio, a biotechnology company pioneering the use of extreme mammal biology and comparative genomics to discover novel therapeutic targets, today announced the designation of a target under its strategic obesity discovery collaboration with Eli Lilly and Company (Lilly), initiated in December, 2023. The designated target, identified using Fauna Bio’s proprietary Convergence™ AI platform, represents a potential first-in-class approach to treating obesity...

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in people with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC). The study m...

BOSTON & STAFFORDSHIRE, England--(BUSINESS WIRE)--Instem announces a 5-year extension of its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA)....

ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of new clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s lead program, AP-101, in patients with ALS. AP-101 is an investigational human-derived antibody directed against misfolded superoxide dismutase 1 (SOD1). AP-101 is...

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that it has completed the acquisition of Intelerad, a leading medical imaging software provider for the healthcare industry, for a base purchase price of $2.3 billion in cash (subject to customary adjustments). Intelerad’s technology and customer base will extend GE HealthCare’s reach into high-growth specialized clinics and ambulatory care environments, complementing the company’s strength in hospital-based imaging. These combined capabil...

BOSTON--(BUSINESS WIRE)--Nia Theraputics' Smart Neurostimulation System is the first neurostimulation device to receive Breakthrough designation for TBI-related memory loss...

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics launches Dyno Psi-Phi, an agentic AI suite for protein binder design, at NVIDIA GTC 2026...

RALEIGH, N.C.--(BUSINESS WIRE)--On February 13, 2026, QHP Capital, L.P. (“QHP”) announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. (“Azurity”). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity’s long-term value creation plan. The transaction was led by HarbourVest Partners, LLC (“HarbourVest”), with Pantheon Ventures, L.P. participating as a significan...